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Abstract Robotic surgical platforms were first developed
with telesurgery in mind. Conceptualized by NASA and the
military to provide surgical expertise to remote locations,
some telesurgical success has been documented, but pro-
gress has been held back by communication bandwidth
limitations. Telepresence surgery, where the surgeon is in
proximity to the patient but is provided with an ergonomic
console equipped with three-dimensional vision and
autonomous control of wristed laparoscopic surgical
instruments and energy sources, has shown efficacy first in
cardiac and then urologic cancer surgery. Interest is cur-
rently focused on the application of this technology in the
field of gynecology, with techniques being described to
perform simple hysterectomy, myomectomy, tubal anas-
tomosis, and pelvic reconstruction procedures. This article
will review the application of robotic- and computer-as-
sisted surgery in the specialty of gynecologic oncology.
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Introduction
Approximately 85,000 women are diagnosed in the United
States each year with gynecologic malignancies. The three
most common cancers affecting these women are uterine,
ovarian and cervical cancer. Treatment often includes
major abdominal surgery to remove the primary cancer –
usually a total hysterectomy – combined with diagnostic
assessment of regional lymph nodes to exclude the pres-
ence of metastatic disease. Adjuvant treatment with che-
motherapy and radiation therapy is then prescribed based
upon surgical staging. Gynecologic oncology patients are
often elderly and have medical co-morbidities such as
obesity, hypertension, diabetes and cardiovascular disease,
which increase their surgical risk. Efforts to reduce surgical
morbidity are needed to improve outcomes in this patient
population.
The most significant advancement in reducing surgical
morbidity in gynecologic oncology over the last 15 years
has been an increased application of minimally invasive
surgical (MIS) techniques for performing simple hyster-
ectomy, radical hysterectomy, and pelvic and para-aortic
lymph node dissection. Feasibility studies have shown
safety and efficacy, and limited series have shown onco-
logic outcomes equivalent to those measured in both
overall and progression-free survival [1]. Patients treated
laparoscopically have been shown to experience less intra-
operative blood loss, less post-operative pain, and shorter
hospital stays than those treated by more traditional ap-
proaches [2]. Despite these patient advantages, MIS for
gynecologic malignancy is still the exception and not the
rule. Naumen et al. surveyed members of the Society of
Gynecologic Oncologists to evaluate treatment patterns for
endometrial cancer. They observed that while 49% of
gynecologic oncologists that responded to the survey stated
that they used laparoscopy to stage endometrial cancer, less
than 8% laparoscopically staged at least half of their pa-
tients. Some reasons cited for this limited use of laparos-
copy in gynecologic oncology include longer operative
times, a steep learning curve to adopt minimally invasive
techniques, lack of training for surgeons who have already
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completed formal medical training, and a perceived infe-
riority of some of the procedures. Robotic-assisted surgical
platforms may overcome many of the shortcomings of
laparoscopy while preserving the patient benefits.
Given that we are describing a new era of surgical
technology and techniques, it is important to understand
some terms. An excellent review written by David Cama-
rillo et al. summarizes the evolution of robotics in surgery.
Dr. Camarillo [3] points out that the term ‘‘robot’’ was
originally coined by playwright Karel Capek in his satirical
drama Rossum’s Universal Robots, written in 1920. He
derived the word robot from the Czech rabota, meaning
slave labor. In the play, machines were made to do mun-
dane work so that people would be free to pursue more
creative interests. In the end, the machines became smarter
than their ‘‘masters’’, ultimately leading to the destruction
of the latter. Today’s surgical ‘‘robots’’ are not by strict
definition robots in that they do not perform independent
tasks and do not exhibit artificial intelligence. Instead, it
might be better to refer to this technology as computer-
assisted surgery. Nonetheless, robotic surgery has already
been accepted as a surrogate descriptor for computer-as-
sisted surgery and will be used throughout this text.
This article chronicles the evolution of one robotic
surgery program in gynecologic oncology with emphasis
on issues pertaining to application, procedure development,
training, research, and cost. This article is not intended to
be a review, mainly because we are at the beginning of an
era of robotics and not at the end or even in the middle.
This article is also not intended to be a comprehensive
description of techniques as such articles will be forth-
coming; it focuses instead on the implications of devel-
oping a robotic surgical program and hints at the promise
this technology holds for improving the quality of life of
gynecology cancer patients by reducing surgical morbidity.
Developing a surgical robotics program
in gynecologic oncology
Surgical robots
There is currently only one robotic surgical platform
commercially available and FDA approved for performing
gynecologic oncology procedures – the daVinci surgical
system (Intuitive Surgical Inc, Sunnyvale, Calif.). Intro-
duced in 1999, the daVinci is comprised of three compo-
nents: the patient side surgical cart, the vision system, and
the surgeon console (Fig. 1). The surgical cart is composed
of three to four arms for controlling a 12-mm three-
dimensional (3D) camera and two to three surgical
instruments. The surgical cart is ‘‘docked’’ to proprietary
laparscopic trocars placed in the patient’s abdomen. The
video signal from each of two charged coupled device
(CCD) cameras (Fig. 2) is then processed independently by
the vision cart, delivered to the surgeon console, and dis-
played on two separate monitors. These two monitors are
focused for the surgeon at the console and viewed as the
‘‘right’’ and ‘‘left’’ eye to reconstruct a 3D immersive
view of the surgical field. The robotic instruments are
‘‘wristed’’, thereby providing 7 df compared with the 4 df
with traditional laparoscopy (Fig. 3). The robotic instru-
ments are controlled by the primary surgeon, who sits away
from the patient at the surgical console via two ‘‘masters’’.
The surgeon’s movements are translated in real-time to the
robotic instruments placed within the patient and are scaled
and processed to reduce tremor and to enhance precision.
The surgical masters are placed inline with the surgeon’s
field of vision so as to restore a more intuitive eye-hand
relationship than that found with traditional laparoscopy.
Also at the surgical console are foot-controlled clutches for
Fig. 1 daVinci Surgical System (photo courtesy of Intuitive Surgical,
Sunnyvale, Calif.)
Fig. 2 InSight 3-D Camera System (photo courtesy of Intuitive
Surgical)
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camera movement, master position, and activation of the
energy sources. The primary surgeon works autonomously
at the console remote from the patient, while a surgical
assist remains scrubbed at the patient’s side to assist with
retraction, suction/irrigation, and passing of needles and
sponges.
The food and drug administration approved the use of
daVinci for performing gynecologic procedures in April
2005 based largely upon preliminary data provided by the
University of Michigan on robotic-assisted uterine
myomectomies and hysterectomies carried out at their
hospital [4]. At that time, there were no published
descriptions of techniques for performing robotic proce-
dures on gynecologic oncology patients.
Robotic surgical training
Following the installation of a daVinci surgical system in
February 2005 at the University of North Carolina, the
author set out to assess the feasibility and efficacy of ro-
botic assistance in performing gynecologic oncology pro-
cedures. Based on over 7 years of experience performing
advanced laparoscopic procedures for the treatment of
gynecologic malignancies, this author sought to translate
these techniques to the robotic platform with the goal of
establishing standardized, reproducible robotic techniques
for performing simple and radical hysterectomy and pelvic
and para-aortic lymph node dissection in the context of
treating cervical, endometrial and early ovarian cancer.
Preparation included an on-line orientation to the daVinci
system, a 2-h dry lab spent suturing and performing simple
dexterity skills with the robotic surgical system, and a
formal porcine training lab provided at East Carolina
University. The skills emphasized during this course in-
cluded a comprehensive understanding of the entire sys-
tem, including set-up, draping, and equipment calibration.
A retroperitoneal dissection, nephrectomy, suturing, knot
tying, and anastomosis was then carried out on a live
porcine model in order to assimilate the robotic system in a
setting that most approximated the skills required to per-
form hysterectomy and node dissection. This training was
completed within 1 week of the first planned robotic-as-
sisted operative case, a simple hysterectomy and bilateral
salpingo-oophorectomy for a 10-cm dermoid ovarian cyst.
Based upon success with this first application, the daVinci
surgical system has been used by the author since May
2005 to successfully perform nearly 150 robotic cases, with
over 80% being performed for the treatment of gynecologic
malignancy.
Procedure development
While there is reference to the staging of gynecologic
malignancy in an early series of robotic-assisted hysterec-
tomy cases, there were no published or even un-published
descriptions of this technique or standardized approaches
to performing robotic-assisted hysterectomy or lymph node
dissection when we began our program [5]. We therefore,
translated an already familiar technique of total laparo-
scopic hysterectomy described by Koh et al. [6] in 1998 for
performing simple hysterectomy, which incorporates a
Zumi uterine manipulator, KOH colpotomizer rings, and a
pneumo-occluder balloon to the daVinci (Cooper Surgical,
Trumbull, Conn.). The KOH system facilitates para-cer-
vical dissection when performing simple hysterectomy and
has been reviewed in many clinical series. For radical
hysterectomy, the uterine manipulator was replaced with a
rectal dilator placed in the vagina and used as a stent to
delineate the vaginal wall for parametrial dissection and
colpotomy. Radical hysterectomy was performed in the
same manner as when performing the surgery abdominally.
Trans-peritoneal lymph node dissection was performed
following the International Federation of Gynecology and
Obstetrics (FIGO) guidelines for the staging of endome-
trial, cervical, and ovarian cancer. All surgical techniques
adhered to the same approaches taken with traditional
laparotomy with respect to anatomic planes and surgical
margins, with the exception that clamps and sutures were
Fig. 3 EndoWrist robotic instrument (photo courtesy of Intuitive
Surgical)
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replaced with bipolar and monopolar energy sources for
vessel sealing. A meticulous prospective collection of
operative times broken down into components, including
the induction of anesthesia and patient positioning, trocar
placement, and the docking of the robotic surgical system;
in addition, the individual components of a hysterectomy
and lymph node dissection were performed for each case in
order to track progress and critically assess areas for
refinement of technique. Nearly all procedures were video
recorded for review by the primary surgeon to facilitate
critical assessment of the technique and streamline the flow
of the operation.
Table 1 summarizes the procedures performed from
May 2005 through October 2006 by the gynecologic
oncology team at the University of North Carolina at
Chapel Hill. Specific surgical outcomes will be reported in
subsequent publications, but many observations can be
mentioned here. First, it must be made clear that we
emphasized the robotic application for simple hysterec-
tomy, radical hysterectomy, and pelvic and para-aortic
lymph node dissection in the context of cervical and
endometrial cancer. Only limited experience exists thus far
for staging early ovarian cancer. This is primarily due to
the design of the current robotic surgical system and the
range of motion of the instruments. In order for daVinci to
reach the upper abdomen, as is necessary in high para-
aortic lymph node dissection, the ports need to be placed
very high on the abdomen. There is a limit as to how high
the ports can be placed and still operate in the deep pelvis
due to the range of motion of the instruments. When
developing these procedures, we were committed to
developing a single docking approach that emphasized
simplicity and reproducibility. While in some patients the
high para-aortics can be reached with the system still
providing enough range of motion to complete hysterec-
tomy and pelvic node dissection, this is not generally true.
This limitation in design has been partially overcome with
the newest generation of daVinci and accounts for the
successful completion of the ovarian staging procedures
listed in our series. However, increasing the ease and
ability to perform true four quadrant surgery will need to be
emphasized in future robotic surgical system design. What
is striking, however, is that the current platform, while not
originally designed to perform gynecologic procedures,
allowed us to treat consecutive patients with both cervical
and endometrial cancer without the need for conversion to
laparotomy. This observation alone provides the clearest
glimpse into the potential advantages of robotic-assisted
surgery, when one considers that this series represents not
only a learning curve, but the initial development of
technique.
Clinical experience
Several reports have been published in the last 2 years that
describe robotic-assisted simple hysterectomy in terms of
technique and experiences [7–10]. While these reports
demonstrate feasibility, they are limited in numbers, and
their results will need to be validated with larger studies.
Reynolds et al. [11] published their initial experience
staging seven patients with gynecologic malignancy, four
patients with endometrial cancer, two with ovarian cancer,
and one with fallopian tube cancer. The authors were able
to complete staging in all patients without conversion to
laparotomy, however, they were required to re-dock the
system in order to perform high para-aortics. They recov-
ered an average of 15 lymph nodes. None of their patients
required blood transfusion, and no significant complica-
tions were experienced. Marchal et al. [12] reported in
2005 on their initial experience with 30 patients. Twelve of
their patients had robotic-assisted surgery for gynecologic
malignancy (seven uterine and five cervix). While details
on the extent of the surgery are not available, these
researchers reported performing Type II radical hysterec-
tomy for some patients, and pelvic node dissection for nine
patients in total. They concluded that robotic-assisted sur-
gery was feasible and more ergonomic than laparoscopy.
We reported our initial experience with robotic-assisted
radical hysterectomy with bilateral pelvic lymphnode dis-
section at the Society of Gynecologic Oncologists meeting
in March 2006. In that report, we compared the surgical
and pathologic outcomes of 13 consecutive robotic-assisted
Type III radical hysterectomies with 48 historic abdominal
radical hysterectomies. All of the robotic procedures were
completed successfully without any conversion to lapa-
rotomy. There were significantly more lymph nodes
recovered robotically than abdominally (33 vs. 22;
P = 0.001), no increase in operative time (median 242 vs.
Table 1 Gynecologic oncology robotic procedures performed be-




Simple hysterectomy with pelvic and para-aortic
nodes
51
Radical hysterectomy with pelvic nodes 39




Ovarian cystectomy in pregnancy 6
Other 6
Total 142
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240 min), less blood loss (100 vs. 400 cc), and no blood
transfusions administered to the robotic-assisted surgery
patients compared with blood transfusions to 8% of the
abdominal controls. Furthermore, all of the robotic-treated
patients were discharged within 24 h, and none required
intra-venous pain medication compared with an average of
three hospital days for the abdominal group.
During a session on laparoscopic lymph node dissection
at the American College of Surgeons, we reported unpub-
lished data on endometrial staging in which we compared a
series of 43 patients staged robotically versus 101 patients
staged laparoscopically. None of the robotic patients were
converted to laparotomy versus 3% for the laparoscopy
group; in addition, significantly more nodes were retrieved
(30 vs. 23, P = 0.004), less blood was lost (63 vs. 142 cc;
P = 0.0001), a shorter operative time was required (163 vs.
213 min; P = 0.002), and a shorter hospitalization period
was necessary (1 vs. 1.2 days; P = 0.04) with the robotic
cohort than with the laparoscopy cohort. The most signif-
icant point may be that we were able to perform compre-
hensive staging on larger women (BMI 33 vs. 29;
P = 0.008). These data suggest that robotic assistance im-
proves upon our already established laparoscopic approach
to the treatment of endometrial cancer.
As our comfort level with the daVinci surgical system
grew through experience, we expanded our indications, as
can be observed in Table 1. In addition, our residents and
fellows in training are routinely involved in all procedures
and are being trained at the console to perform first the
hysterectomy and then pelvic node dissection. We have
found that training residents in this setting is safe, and our
early experience would suggest that their learning curve is
faster than with laparoscopy due to the intuitive nature of
the system. The two gynecologic oncology fellows that
have been exposed to robotics and subsequently graduated
are both actively using robotics in their respective prac-
tices, thereby demonstrating that our investment in their
learning robotics as part of their oncology training was
worthwhile. It will be important for training programs to
balance the need for the teachers to learn in order to then
teach the students. It is this author’s belief that robotics
enhances the training of anatomy and technique by
emphasizing precision. Issues such as certification of
graduating trainees will need to be standardized as training
programs become more widespread. The Society of
Gynecologic Oncologists as well as the American College
of Obstetricians and Gynecologists should take a proactive
role in standardizing training and certification.
Costs and institutional dynamics
Cost analysis is an important and difficult task when
evaluating any new technology. When establishing a
robotics program, there is clearly a significant fixed cost
associated with the purchase of a robotic surgical system.
The first cost includes the purchase price of the robotic
system, which ranges between $1,000,000 and $1,500,000
and requires a 10% annual maintenance fee for repair and
service as well as software upgrades to the system. The
second cost is the procedure disposable cost, which in-
cludes the robotic instruments ($ 200/use), drapes to
maintain sterility of the system, and a few other accessories
and ports required to perform the surgery that are specific
to robotics. The third cost is the cost of training new per-
sonnel and initial delays in setup time and procedure time
during the learning curve. The fourth cost is the expense of
training and/or proctoring until the surgeon is certified.
This cost is highly variable. depending upon institutional
policies and the availability and cost of trained proctors.
Although we have not yet performed a detailed cost
analysis of our robotics program, some observations can be
shared. The fixed cost depends greatly upon the number of
cases being performed over the amortized life span of the
robotic system. For example, if a $1,500,000 robotic sys-
tem with a 10% per year service contract is amortized over
7 years, then the fixed cost for a single surgical system is
approximately $365,000 per year. If two cases are per-
formed per day, 5 days/week for a total of 520 cases
annually, the fixed cost per case is approximately $700.
This cost would increase dramatically if the number of
cases performed is substantially less. The disposable costs
for our procedures are approximately $1000 (three to four
robotic instruments, drapes, one to two disposable trocars).
This cost is typically less than the disposable costs for
comparable cases performed laparoscopically at our insti-
tution. The added operative costs are offset by a shortened
hospital stay and a decreased need for post-operative pain
medication compared with open abdominal surgery. The
cost offset becomes less when comparing robotic to lapa-
roscopic techniques. We have observed that the operating
room setup for robotic cases is approximately 15 min
longer than for laparoscopy. Over time, our operative times
have become substantially less compared with laparoscopy
and comparable to laparotomy. Docking the system quickly
becomes trivial in terms of time, and it takes an experi-
enced team less than 5 min. In summary, when analyzing
cost, it is important to maximize utilization, to strive for
efficiency, both in preparation for and during the operation,
and to balance increased procedure costs with post-opera-
tive care plans that yield early discharge from the hospital.
An approximate 10% return on the investment has been
estimated for hospitals that have initiated urology robotics
programs; this is due largely to changes in regional referral
patterns of patients for specialized services, an increase in
ancillary charges, and shorter patient stays. Whether a
similar return on the investment will be observed in
J Robotic Surg (2007) 1:31–37 35
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gynecologic oncology will depend upon whether robotics
allows more surgeons to adapt minimally invasive surgical
procedures to their practice. As more and more systems are
being installed, the ‘‘novelty’’ of having a robot will dis-
appear, and regional growth of programs will stabilize.
Robotics programs will need to pay for themselves on a per
case basis. Furthermore, competition for access to robotic
systems is already a major problem for many centers as
multiple surgeons within a department and between
departments are sharing an expensive and limited resource.
We currently operate two robotic systems at the University
of North Carolina; these systems support programs in
Urology, Gynecology, gynecologic oncology, Pediatric
Surgery, and General Surgery. The coordination of
scheduling and cooperation between surgeons has become
increasingly critical in maintaining efficient utilization of
the systems while serving the needs of each individual
surgeon’s growing program. Ultimately, widespread
growth of robotics will require that costs come down. This
will most likely happen when competitors enter the market,
and indications are validated and expanded across surgical
disciplines, thus increasing the demand based upon supe-
rior patient outcomes. Surgical robotics will have longevity
only if demonstrated to be ‘‘better medicine’’ not better
business.
Summary
A great deal of progress has occurred in the field of robotic
surgery and gynecologic oncology over the last 2 years,
and this has generated a great deal of interest within our
specialty. Despite this development, this technology and its
application in gynecologic oncology are still in their in-
fancy. We and others have established comprehensive ro-
botic programs incorporating routine clinical application in
an effort to develop standardized procedures and evaluate
efficacy. We have presented early clinical outcomes at
national meetings and the publication of larger case series
is soon to follow. Furthermore, we have developed detailed
procedure manuals with video documentation of tech-
niques so that surgeons new to robotics have the benefit of
a standardized approach. A few of us with significant
experience have established training programs that allow
surgeons to come and learn from our experience and then
observe live robotic cancer cases. The potential for robotic
and computer-assisted surgical devices to revolutionize our
specialty by nearly eliminating post-operative morbidity
while preserving radicality and the tenets of oncology
surgery for a large majority of the patients that we treat
seems to be right around the corner. However, it is our
responsibility as a specialty caring for women with cancer
to standardize the technique and subject our outcomes to
peer review before we can recognize this development as a
new standard of care. In order to do this, it is essential to
establish a national registry of cases for the research,
expansion, and support of training centers of excellence
and partnering with industry in order to develop tomor-
row’s tools.
The brilliance of this technology is simple: by restoring
dexterity, 3D vision, and autonomy to the abdominal sur-
geon while leveraging the patient outcome advantages that
come from minimally invasive techniques, better surgical
outcomes will be achieved. In addition, as has been seen in
Urology, we should experience shallower learning curves
and greater generalizability to more practitioners previ-
ously discouraged by the limitations of standard laparos-
copy. Many naive surgeons have described robotic-assisted
surgery as a ‘‘fancy laparoscope’’. On the contrary, lapa-
roscopy was an early evolutionary step toward robotics,
and we are experiencing that evolution now. If the success
witnessed in Urology and the treatment of prostate cancer
is an indicator for our specialty, and I believe it should be,
robotic and computer-assisted technology will allow more
surgeons to perform a greater diversity of complex mini-
mally invasive procedures. As costs are contained, even
simple, more common procedures such as hysterectomy
will be performed with less morbidity to the patient than
even laparoscopy. It will truly be an exciting decade as we
witness the evolution of a new surgical paradigm in
gynecologic oncology.
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